Evidence map›Paper›PMID 39183260›Full record

ArticleJournal of cellular and molecular medicine2024

A comprehensive prognostic and immune infiltration analysis of UBA1 in pan-cancer: A computational analysis and in vitro experiments.

Can Chen, Yiwei Li, Zhenzhen Chen, Pengfei Shi, Yun Li, Shenxian Qian

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Can ChenDepartment of Hematology, Affiliated Hangzhou First People's Hospital, West Lake University, School of Medicine, Hangzhou, China.ORCID 0000-0001-9268-5323
Yiwei LiDepartment of Hematology, Affiliated Hangzhou First People's Hospital, West Lake University, School of Medicine, Hangzhou, China.
Zhenzhen ChenDepartment of Hematology, Affiliated Hangzhou First People's Hospital, West Lake University, School of Medicine, Hangzhou, China.
Pengfei ShiDepartment of Hematology, Affiliated Hangzhou First People's Hospital, West Lake University, School of Medicine, Hangzhou, China.
Yun LiTeam of neonatal & infant development, health and nutrition, NDHN. School of Biology and Pharmaceutical Engineering, Wuhan Polytechnic University, Wuhan, China.ORCID 0000-0002-0804-1195
Shenxian QianDepartment of Hematology, Affiliated Hangzhou First People's Hospital, West Lake University, School of Medicine, Hangzhou, China.ORCID 0000-0003-1026-4395

Funding

Hangzhou Medical health science and technology Major Project Z20210039Hangzhou science and technology Major Project 202004A15Zhejiang Province Traditional Chinese medicine science and technology project 2023ZR122Zhejiang Provincial Medical and Health Science and Technology Plan Project 2021ky881
6 · The paper itself

Abstract

Ubiquitin like modifier activating enzyme 1 (UBA1) plays an important role in immune regulation and cellular function. However, the functional mechanism and role of UBA1 in pan-cancer have not been fully elucidated and its value in haematological tumours (diffuse large B cell lymphoma (DLBC/DLBCL) and acute myeloid leukaemia (AML/LAML)) has not been explored. We conducted a comprehensive analysis of the functional mechanism and role of UBA1 in pan-cancer using multiple databases, including differential expression analysis, clinical pathological staging analysis, prognosis analysis and immune analysis. Then, we confirmed the function of UBA1 in haematological tumours through cell experiments. The results showed that the expression of UBA1 was significantly increased in most cancers and the differential expression of UBA1 was mainly concentrated in digestive tumours, haematological tumours and brain tumours. Moreover, the high expression of UBA1 had poor prognosis in most tumours, which may be related to its involvement in various cancer-related pathways such as cell cycle, as well as its methylation level, protein phosphorylation level, immune cell infiltration and immune therapy response. Cell experiments have confirmed that UBA1 can significantly regulate the cycle progression and apoptosis of DLBCL cells and AML cells. Therefore, UBA1 may be a potential therapeutic target for haematological tumours. In summary, our study not only comprehensively analysed the functional mechanisms and clinical value of UBA1 in pan-cancer, but also validated for the first time the regulatory role of UBA1 in haematological tumours.

Indexed as

Computational BiologyGene Expression Regulation, NeoplasticUbiquitin-Activating EnzymesApoptosisBiomarkers, TumorCell Line, TumorCell ProliferationHumansNeoplasmsPrognosisBiomarkers, TumorUBA1 protein, humanUbiquitin-Activating Enzymescancer immunityHaematological tumoursPan‐cancerprognosisUBA1

Identifiers

PMID39183260
PMCPMC11345122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.